Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Jazz Pharmaceuticals plc and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$241.38+0.4%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026
Jazz sells low-sodium oxybate medicine for narcolepsy and idiopathic hypersomnia, plus epilepsy and cancer drugs to patients through pharmacies and hospitals.
Company outlook: revenue of $4.8B to $4.9B for Fiscal year 2026 — up 12.8% on a year earlier